Table 1 Baseline characteristics of the trial participants.

From: Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin

 

Linagliptin (n = 51)

Empagliflozin (n = 46)

Male (%)

14 (27.5%)

23 (50%)*

Age (years)

58.7 ± 10.2

58.9 ± 9.9

Diabetes duration (years)

11.1 ± 6.2

13.0 ± 6.1

History of hypertension (%)

26 (51%)

28 (60.9%)

History of hyperlipidemia (%)

47 (92.2%)

38 (82.6%)

SBP (mm Hg)

130.9 ± 12.9

132.0 ± 10.4

DBP (mm Hg)

73.9 ± 8.5

75.8 ± 8.3

HbA1c % (mmol/mol)

9.0 ± 1.2 (75 ± 13)

9.2 ± 1.4 (77 ± 15)

FPG (mg/dL)

175.7 ± 61.3

191.7 ± 74.6

Creatinine (mg/dL)

0.84 ± 0.23

0.90 ± 0.26

eGFR (mL/min/1.73 m2)

84.8 ± 35.2

81.6 ± 25.2

ALT (IU/L)

27.9 ± 24.5

23.5 ± 18.3

Total cholesterol (mg/dL)

189.4 ± 42.6

181.8 ± 39.1

Triglyceride (mg/dL)

180.6 ± 173.2

145.2 ± 79.5

LDL-C (mg/dL)

100.4 ± 28.7

99.7 ± 32

HDL-C (mg/dL)

49.5 ± 10.4

51.2 ± 12.1

Use of metformin (%)

21 (41.2%)

18 (39.1%)

Total insulin dose (units/day)

66.0 ± 22.9

67.0 ± 23.7

Weight (kg)

70.6 ± 10.6

71.4 ± 12.6

Body mass index (kg/m2)

28.0 ± 3.5

27.7 ± 5.0

Muscle mass (kg)

44.2 ± 7.4

46.5 ± 7.6

Protein (kg)

9.5 ± 1.7

10.1 ± 1.7

Total body water (kg)

34.7 ± 5.7

36.4 ± 5.9

Intracellular water (kg)

20.6 ± 3.5

21.5 ± 3.5

Extracellular water (kg)

14.1 ± 2.3

14.8 ± 2.4

Body fat mass (kg)

22.4 ± 5.6

20.8 ± 7.6

Visceral fat mass (kg)

3.1 ± 1.1

2.9 ± 1.3

Subcutaneous fat mass (kg)

19.4 ± 4.6

17.9 ± 6.4

  1. The data presented are n (%) or mean ± SD.
  2. SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, ALT alanine aminotransferase, LDL-C low density lipoprotein, HDL-C High density lipoprotein.
  3. *p value < 0.05.
Back to article page